While targeting NFAT also shows potent therapeutic efficacy against GVHD [40], its clinical efficacy and PP2B-NFAT or PP2B-GSK-3β activation in CD4+ lymphocytes of GVHD patients need to be validated. The gene discussed is CD4; the disease is graft versus host disease.